Recent data indicates that retatrutide, a innovative medication, could represent a major step in size loss . This treatment combines the effects of a GLP-1 analog and a GIP agonist , seemingly offering a enhanced benefit than existing approaches . Patient trials have revealed promising findings , including substantial declines in size and gains in